Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial

Phase III noninferiority trial examining efficacy and safety of converting stable renal transplant recipients from twice-daily tacrolimus to a novel extended-release once-daily tacrolimus formulation (LCPT) with a controlled agglomeration technology. Controls maintained tacrolimus twice daily. The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bunnapradist, S, Ciechanowski, K, West-Thielke, P, Mulgaonkar, S, Rostaing, L, Vasudev, B, Budde, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613750/
https://www.ncbi.nlm.nih.gov/pubmed/23279614
http://dx.doi.org/10.1111/ajt.12035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613750/
https://www.ncbi.nlm.nih.gov/pubmed/23279614
http://dx.doi.org/10.1111/ajt.12035

Ejemplares similares